Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn’s disease
Open Access
- 23 August 2021
- journal article
- research article
- Published by Springer Nature in Microbiome
- Vol. 9 (1) , 1-16
Abstract
Background: An Escherichia coli (E. coli) pathotype with invasive properties, first reported by Darfeuille-Michaud and termed adherent-invasive E. coli (AIEC), was shown to be prevalent in up to half the individuals with Crohn’s Disease (CD), suggesting that these bacteria could be involved in the pathophysiology of CD. Among the genes related to AIEC pathogenicity, fim has the potential to generate an inflammatory reaction from the intestinal epithelial cells and macrophages, as it interacts with TLR4, inducing the production of inflammatory cytokines independently of LPS. Therefore, targeting the bacterial adhesion of FimH-expressing bacteria seems a promising therapeutic approach, consisting of disarming bacteria without killing them, representing a selective strategy to suppress a potentially critical trigger of intestinal inflammation, without disturbing the intestinal microbiota. Results: We analyzed the metagenomic composition of the gut microbiome of 358 patients with CD from two different cohorts and characterized the presence of FimH-expressing bacteria. To assess the pathogenic role of FimH, we used human intestinal explants and tested a specific FimH blocker to prevent bacterial adhesion and associated inflammation. We observed a significant and disease activity-dependent enrichment of Enterobacteriaceae in the gut microbiome of patients with CD. Bacterial FimH expression was functionally confirmed in ileal biopsies from 65% of the patients with CD. Using human intestinal explants, we further show that FimH is essential for adhesion and to trigger inflammation. Finally, a specific FimH-blocker, TAK-018, inhibits bacterial adhesion to the intestinal epithelium and prevents inflammation, thus preserving mucosal integrity. Conclusions: We propose that TAK-018, which is safe and well tolerated in humans, is a promising candidate for the treatment of CD and in particular in preventing its recurrence.Keywords
Funding Information
- Enterome
This publication has 59 references indexed in Scilit:
- Point Mutations in FimH Adhesin of Crohn's Disease-Associated Adherent-Invasive Escherichia coli Enhance Intestinal Inflammatory ResponsePLOS Pathogens, 2013
- MOCAT: A Metagenomics Assembly and Gene Prediction ToolkitPLOS ONE, 2012
- Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathologyProceedings of the National Academy of Sciences, 2011
- Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypesBMC Genomics, 2010
- Similarity and Divergence among Adherent-Invasive Escherichia coli and Extraintestinal Pathogenic E. coli StrainsJournal of Clinical Microbiology, 2009
- Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAMJournal of Experimental Medicine, 2009
- FimH Adhesin of Type 1 Fimbriae Is a Potent Inducer of Innate Antimicrobial Responses Which Requires TLR4 and Type 1 Interferon SignallingPLOS Pathogens, 2008
- Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileumThe ISME Journal, 2007
- CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn diseaseJournal of Clinical Investigation, 2007
- MUSCLE: multiple sequence alignment with high accuracy and high throughputNucleic Acids Research, 2004